Login to Your Account

Memory, Roche Craft CNS Deal With Potential Value Of $150M

By Karen Young

Wednesday, July 31, 2002
Memory Pharmaceuticals Corp., a company focused on neurodegenerative diseases, secured its first licensing agreement, a potential $150 million deal with F. Hoffmann-La Roche Ltd. focused on the development of compounds for Alzheimer's disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription